ArticleDEN open2026
Long-term Outcomes of Intraductal Fully Covered Self-Expandable Metal Stents for Anastomotic Biliary Strictures After Living Donor Liver Transplantation: Clinical and Economic Evaluation.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Anastomotic biliary stricture (ABS) is a common complication following living donor liver transplantation (LDLT). Although plastic stents (PSs) have traditionally been the standard treatment, fully covered self-expandable metal stents (FCSEMSs) have recently gained attention because of their potential advantages. This study aimed to retrospectively analyze cases of ABS after LDLT that were treated with intraductal FCSEMSs (ID-FCSEMS) at our institution. Methods: This study included 46 adult patients who developed anastomotic bile duct stricture following LDLT. Twenty patients underwent ID-FCSEMS placement, and 22 patients underwent PS placement. The FCSEMSs were scheduled for removal after 16 weeks. Results: Placement of FCSEMSs was technically successful in all 20 patients. Early complications included cholangitis in five patients, whereas late complications included one case of stent migration and one case of obstructive cholangitis. Clinical success was achieved in 16 patients. Restenosis occurred in two patients. No significant differences were found between the FCSEMS group and the PS group in terms of reimbursement points (as defined by the Japanese medical fee schedule), number of hospitalizations, and total inpatient days. Conclusions: ID-FCSEMSs demonstrate a high success rate and favorable long-term outcomes for ABS after LDLT. Although no significant difference in cost reduction is observed, ID-FCSEMSs are a safe and effective therapeutic option for ABS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.